Astex Therapeutics
436 Cambridge Science Park
Milton Road
Cambridge
CB4 0QA
United Kingdom
Tel: 44-0-1223-226200
Fax: 44-0-1223-226201
Website: http://www.astex-therapeutics.com/
Email: info@astex-therapeutics.com
39 articles about Astex Therapeutics
-
PharmaVentures Ltd Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
9/9/2011
-
SuperGen, Inc. Completes Acquisition of Astex Therapeutics
7/20/2011
-
SuperGen, Inc. Stockholders Approve Stock Issuance In Connection with the Proposed Acquisition of Astex Therapeutics
6/17/2011
-
Astex Therapeutics Achieves Milestones in GlaxoSmithKline Collaboration
5/3/2011
-
Astex Therapeutics Announces Commencement of Phase I Study for AZD5363 in Anti-Cancer Collaboration with AstraZeneca PLC
4/12/2011
-
SuperGen, Inc. and Astex Therapeutics Enter Definitive Merger Agreement, Creating a Financially Strong, International Oncology Company Astex Pharmaceuticals, Inc.
4/7/2011
-
Astex Therapeutics Receives Milestone from Wellcome Trust for Pioneering HCV Research
2/1/2011
-
Astex Therapeutics Announces Milestone in Oncology Collaboration
1/11/2011
-
Astex Therapeutics to Present at Biotech Showcase 2011
1/5/2011
-
Astex Therapeutics and the NCIC Clinical Trials Group Announce Start of Phase II Clinical Study of AT9283 in Multiple Myeloma
11/4/2010
-
Milestone Transition in Astex Therapeutics Alzheimer's Disease Collaboration with AstraZeneca PLC
10/22/2010
-
Astex Therapeutics and Multiple Myeloma Research Consortium Announce Start of Phase II Clinical Study of AT7519 in Multiple Myeloma
8/12/2010
-
Astex Therapeutics Scientists Describe Novel HSP90 Inhibitors In Two Key Publications In Journal Of Medicinal Chemistry
7/29/2010
-
Encouraging Interim Data From A Phase I Study Of Astex Therapeutics's HSP90 Inhibitor AT13387 To Be Presented At American Society of Clinical Oncology
6/2/2010
-
Dr Ismail Kola Joins Astex Therapeutics Board
5/25/2010
-
Clinical Candidate From PKB/AKT Collaboration With Astex Therapeutics Selected by AstraZeneca PLC
1/7/2010
-
Astex Therapeutics Announces £300 Million ($500 Million) Strategic Drug Discovery Alliance with GlaxoSmithKline (JOBS)
11/12/2009
-
Astex Therapeutics Reports Positive Data From Its Phase I Study Of AT9283 At The American Society of Clinical Oncology Annual Meeting 2009
5/26/2009
-
Astex Therapeutics Reports Positive Clinical Biomarker Data from its Phase I study on CDK Inhibitor AT7519 at the American Association for Cancer Research Annual Meeting 2009
4/14/2009
-
Astex Therapeutics Presents Key Data Differentiating its Phase I HSP90 inhibitor, AT13387, at the American Association for Cancer Research Annual Meeting 2009
4/14/2009